University of Cincinnati

Vyvanse is FDA-approved for moderate to severe binge eating disorder

Thursday, February 5, 2015

The FDA has approved Shire’s Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (BED) in adults, shown to significantly reduce the mean number of binge days per week. Vyvanse is not indicated or recommended for weight loss or the treatment of obesity. Other sympathomimetic drugs used for weight loss have been associated with serious cardiovascular reactions.

[Read More]

AiCure tests artificial intelligence in opioid trial

Monday, November 24, 2014

AiCure, a New York-based artificial intelligence company providing advanced facial recognition and motion-sensing technology to monitor medication ingestion, has announced the start of a major clinical trial to monitor and intervene with patients receiving medication as maintenance therapy for opioid addiction.

[Read More]

Cincinnati area hospitals, universities form collaborative IRB

Wednesday, November 27, 2013

A group of hospitals and research institutions across Cincinnati and Northern Kentucky has formed a collaborative Institutional Review Board (IRB) agreement that will allow any of the six participating sites to serve as the IRB of record for research conducted across multiple participating study sites.

[Read More]